Management of acute promyelocytic leukemia |
| |
Authors: | Tallman Martin S Nabhan Chadi |
| |
Institution: | (1) Division of Hematology/Oncology, Northwestern University Medical School, Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair Street, Suite 850, 60611 Chicago, IL, USA |
| |
Abstract: | Acute promyelocytic leukemia (APL) has become the most potentially curable subtype of acute myeloid leukemia (AML) in adults.
With current treatment strategies that incorporate all-trans retinoic acid (ATRA), long-term disease-free survival and potential
cure rates of 70% to 80% can be expected. Such progress reflects what can be accomplished with insights into the molecular
pathogenesis of leukemia, identification of a molecular target, and rapid accrual to a series of clinical trials. The leukemic
promyelocytes from patients with APL are uniquely susceptible to a variety of novel agents in addition to ATRA, including
arsenic trioxide, and in preliminary studies, gemtuzumab ozogamicin, the immunoconjugate comprised of an anti-CD33 monoclonal
antibody linked to the potent cytotoxic agent calicheamicin. Incorporation of such agents into the treatment of patients with
high-risk disease may be an important future direction to pursue. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|